If a molecular definition is accepted (i.e. a typical methylation class, a MAPK alteration and CDKN2A/B loss), the morphological spectrum is much wider and needs to be considered in the context of any moderately cellular astrocytoma [15]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).